Two Star Manager LLC Acquires 1,905 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Two Star Manager LLC boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 9.6% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 21,698 shares of the medical research company's stock after purchasing an additional 1,905 shares during the quarter. Thermo Fisher Scientific comprises 5.2% of Two Star Manager LLC's portfolio, making the stock its 9th largest position. Two Star Manager LLC's holdings in Thermo Fisher Scientific were worth $10,797,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Bernard Wealth Management Corp. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $25,000. Ameriflex Group Inc. purchased a new stake in Thermo Fisher Scientific in the fourth quarter valued at approximately $30,000. Keystone Global Partners LLC purchased a new stake in Thermo Fisher Scientific in the first quarter valued at approximately $31,000. IMA Advisory Services Inc. purchased a new stake in Thermo Fisher Scientific during the first quarter worth approximately $35,000. Finally, Navigoe LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth approximately $37,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TMO. William Blair began coverage on shares of Thermo Fisher Scientific in a research note on Monday. They set an "outperform" rating for the company. Hsbc Global Res downgraded shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 24th. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price objective for the company in a research note on Friday, July 11th. Wells Fargo & Company decreased their price objective on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, HSBC reiterated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average target price of $593.00.

Thermo Fisher Scientific Stock Up 3.4%

Shares of TMO stock traded up $16.4780 on Friday, hitting $500.2380. The stock had a trading volume of 1,778,365 shares, compared to its average volume of 2,406,376. The firm has a market capitalization of $188.89 billion, a price-to-earnings ratio of 28.93, a P/E/G ratio of 2.58 and a beta of 0.74. The stock's 50 day moving average is $443.02 and its 200-day moving average is $457.46. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business's quarterly revenue was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be issued a $0.43 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of the company's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 295 shares of the company's stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $500.04, for a total transaction of $147,511.80. Following the completion of the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,591,606.96. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 18,896 shares of company stock worth $8,593,838 over the last ninety days. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.